Rein Therapeutics (NASDAQ:RNTX) Major Shareholder Voss Capital, Lp Acquires 104,183 Shares

Rein Therapeutics Inc. (NASDAQ:RNTX) major shareholder Voss Capital, Lp bought 104,183 shares of the stock in a transaction on Friday, November 14th. The stock was purchased at an average price of $1.22 per share, for a total transaction of $127,103.26. Following the purchase, the insider directly owned 926,441 shares of the company’s stock, valued at approximately $1,130,258.02. This represents a 12.67% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Voss Capital, Lp also recently made the following trade(s):

• On Tuesday, October 28th, Voss Capital, Lp acquired 178,392 shares of Rein Therapeutics stock. The stock was purchased at an average price of $1.39 per share, for a total transaction of $247,964.88.
• On Monday, October 27th, Voss Capital, Lp purchased 97,482 shares of Rein Therapeutics stock. The shares were acquired at an average price of $1.37 per share, for a total transaction of $133,550.34.
• On Friday, October 24th, Voss Capital, Lp bought 30,176 shares of Rein Therapeutics stock. The shares were bought at an average price of $1.39 per share, for a total transaction of $41,944.64.

Rein Therapeutics Stock Performance

RNTX remained flat at $1.22 on Tuesday. The company had a trading volume of 237,964 shares, compared to its average volume of 306,904. The company has a market capitalization of $28.44 million, a PE ratio of -0.46 and a beta of 1.15. The stock’s fifty day simple moving average is $1.31 and its two-hundred day simple moving average is $1.47. Rein Therapeutics Inc. has a 12-month low of $1.04 and a 12-month high of $3.50.

Rein Therapeutics (NASDAQ:RNTX) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.03. Analysts expect that Rein Therapeutics Inc. will post -1.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Rein Therapeutics

Several institutional investors have recently bought and sold shares of RNTX. Senvest Management LLC bought a new stake in shares of Rein Therapeutics during the second quarter worth $323,000. Sigma Planning Corp acquired a new position in Rein Therapeutics during the 2nd quarter worth about $387,000. University of Texas Texas AM Investment Management Co. acquired a new position in Rein Therapeutics during the 2nd quarter worth about $716,000. Chicago Partners Investment Group LLC bought a new stake in Rein Therapeutics during the 2nd quarter worth about $64,000. Finally, Exencial Wealth Advisors LLC acquired a new stake in Rein Therapeutics in the 2nd quarter valued at about $43,000. Institutional investors own 90.89% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on RNTX shares. HC Wainwright began coverage on Rein Therapeutics in a report on Monday, September 22nd. They issued a “buy” rating and a $10.00 price target for the company. Loop Capital set a $6.00 price objective on Rein Therapeutics in a research report on Monday, November 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Wednesday, October 8th. Finally, Brookline Capital Management raised shares of Rein Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, November 3rd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $8.00.

About Rein Therapeutics

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.